Short Interest in UCB SA (OTCMKTS:UCBJY) Drops By 60.4%

UCB SA (OTCMKTS:UCBJY) was the target of a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 2,283 shares, a decline of 60.4% from the June 30th total of 5,769 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 58,706 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on UCBJY shares. Zacks Research upgraded UCB from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Barclays cut UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Jefferies Financial Group raised UCB to a “moderate sell” rating in a report on Monday, June 22nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, UCB presently has an average rating of “Hold”.

UCB Price Performance

Shares of OTCMKTS UCBJY opened at $139.01 on Monday. The firm has a 50 day moving average of $143.75 and a 200 day moving average of $147.85. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. UCB has a 12-month low of $103.43 and a 12-month high of $168.76.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.